

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT CE APPROVAL OF ENO™ SERIES PACEMAKER FOR LBBAP INDICATION

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business progress of the Group.

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) is pleased to announce that, recently, the ENO™ Series pacemakers independently developed by the Group have received CE approval for the left bundle branch area pacing (“**LBBAP**”) indication. To date, all six of the Group’s CE-certified pacemakers have been approved for the LBBAP indication. Paired with the commercialized FLEXIGO™ 3D LBBAP delivery system and Vega™ M58 leads, the Group now possesses with a complete solution for LBBAP therapy, enabling it to meet the clinical needs of a broader patient population and further diversify its revenue streams.

As a leading international physiological pacing technique, LBBAP therapy enables electrical signals to propagate along the heart’s intrinsic conduction system by precisely implanting an electrode into the left bundle branch and its adjacent region, thereby achieving synchronized left and right ventricular contraction and significantly improving cardiac pumping efficiency. Closely replicating physiological pacing, this therapy effectively reduces the risk of heart failure caused by long-term ventricular dyssynchrony. It is suitable for patients with bradycardia, conduction block, and other indications, significantly improving patients’ quality of life and long-term prognosis. As a significant upgrade to and alternative for conventional right ventricular pacing and biventricular pacing, LBBAP has received explicit recommendations in domestic and international guidelines, and its clinical status is rapidly ascending.

The Group's product matrix for LBBAP therapy consists of the following major products:

ALIZEA™ Series Pacemaker

- The world's first CE-certified hybrid pacing system that is magnetic resonance imaging ("MRI") conditional with cross-brand lead compatibility;
- Integrated with Bluetooth communication functionality to support wireless connectivity with the SmartTouch™ tablet programmer and remote monitoring via SmartView Connect™.

ENO™ Series Pacemaker

- The world's smallest transvenous pacemaker, compatible with MRI examinations;
- Features AutoMRI™ intelligent MRI adaptation technology, which automatically recognizes magnetic fields and switches operating modes to ensure scan safety and pacing parameter stability;
- Equipped with sleep apnea monitoring functionality, expanding its clinical monitoring value.

FLEXIGO™ 3D LBBAP Delivery System

- Features a controllable navigation and precise positioning design to assist physicians in stably reaching the target anatomical regions;
- Equipped with eight optional catheter sheaths and dedicated cutters to adapt to different patient anatomical structures and lead specifications, ensuring implantation accuracy and operational reliability.

Looking ahead, leveraging over 60 years of profound expertise in its cardiac rhythm management business regarding active implantable devices, remote monitoring and sensor algorithms, the Group will deeply integrate the technical strengths of its structural heart disease business in passive intervention, delivery systems, valve design, biomaterials and hemodynamic monitoring. The Group aims to accelerate innovative R&D and global commercialization in the field of heart failure, striving to provide global patients with innovative integrated device management solutions that cover all etiologies, all stages, and the entire care cycle of heart failure, thus benefiting global patients with better and more accessible innovative therapies.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, May 10, 2026

As of the date of this announcement, the executive Directors are Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Mr. Chen Guoming, Dr. Brian Chang, Mr. Deng Aoyi and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.